非小细胞肺癌的治疗：精准医学的多种选择。
Treatments for Non-Small-Cell Lung Cancer: The Multiple Options for Precision Medicine.
机构信息
Medical Oncology, Centre Hospitalier Universitaire Nantes, Nantes University, F-44000 Nantes, France.
Department of Medical Oncology, Hospital Foch, F-92150 Suresnes, France.
出版信息
Curr Oncol. 2022 Sep 28;29(10):7106-7108. doi: 10.3390/curroncol29100558.
Abstract
In recent years, advances in molecular diagnostics have transformed the management of advanced non-small-cell lung cancer (NSCLC), allowing for increasingly personalized approaches [...].
摘要
近年来，分子诊断学的进步改变了晚期非小细胞肺癌（NSCLC）的治疗管理方式，使越来越多的治疗方法能够实现个体化。
相似文献
1
Treatments for Non-Small-Cell Lung Cancer: The Multiple Options for Precision Medicine.非小细胞肺癌的治疗：精准医学的多种选择。
Curr Oncol. 2022 Sep 28;29(10):7106-7108. doi: 10.3390/curroncol29100558.
2
Advancements in NSCLC: From Pathophysiological Insights to Targeted Treatments.非小细胞肺癌的进展：从病理生理学研究进展到靶向治疗。
Am J Clin Oncol. 2024 Jun 1;47(6):291-303. doi: 10.1097/COC.0000000000001088. Epub 2024 Feb 20.
3
Toward personalized treatment approaches for non-small-cell lung cancer.针对非小细胞肺癌的个体化治疗方法。
Nat Med. 2021 Aug;27(8):1345-1356. doi: 10.1038/s41591-021-01450-2. Epub 2021 Aug 12.
4
Precision medicine in non-small cell lung cancer: Current applications and future directions.精准医学在非小细胞肺癌中的应用：现状与未来方向。
Semin Cancer Biol. 2022 Sep;84:184-198. doi: 10.1016/j.semcancer.2020.07.009. Epub 2020 Jul 27.
5
Personalizing therapy in advanced non-small cell lung cancer.晚期非小细胞肺癌的个体化治疗。
Semin Respir Crit Care Med. 2013 Dec;34(6):822-36. doi: 10.1055/s-0033-1358552. Epub 2013 Nov 20.
6
[Personalized therapy of lung cancer - current standard and future challenges].[肺癌的个性化治疗——当前标准与未来挑战]
Dtsch Med Wochenschr. 2017 Nov;142(22):1660-1668. doi: 10.1055/s-0043-114486. Epub 2017 Oct 27.
7
The lung and winding road: twists and turns on the way to personalized NSCLC therapy.肺部与曲折之路：非小细胞肺癌个性化治疗之路上的波折
Curr Pharm Des. 2014;20(24):3861-2. doi: 10.2174/13816128113196660766.
8
Personalized medicine in lung cancer: what we need to know.肺癌个体化医学：我们需要了解的内容。
Nat Rev Clin Oncol. 2011 Aug 23;8(11):661-8. doi: 10.1038/nrclinonc.2011.126.
9
[The molecular markers related to personalized therapy of non-small cell lung cancer].[与非小细胞肺癌个体化治疗相关的分子标志物]
Zhongguo Fei Ai Za Zhi. 2011 Mar;14(3):292-6. doi: 10.3779/j.issn.1009-3419.2011.03.17.
10
Management of non-small cell lung cancer in the era of personalized medicine.个性化医疗时代的非小细胞肺癌管理
Int J Biochem Cell Biol. 2016 Sep;78:173-179. doi: 10.1016/j.biocel.2016.07.011. Epub 2016 Jul 15.
引用本文的文献
1
Radiomic Analysis and Liquid Biopsy in Preoperative CT of NSCLC: An Explorative Experience.非小细胞肺癌术前CT的影像组学分析与液体活检：一项探索性经验
Thorac Cancer. 2025 Jul;16(13):e70115. doi: 10.1111/1759-7714.70115.
2
Identification of plasminogen activator urokinase receptor-related non-coding RNA and immune prognostic signature for non-small cell lung cancer.非小细胞肺癌中纤溶酶原激活物尿激酶受体相关非编码RNA的鉴定及免疫预后特征
Clinics (Sao Paulo). 2025 Jun 24;80:100711. doi: 10.1016/j.clinsp.2025.100711.
3
Pseudolaric Acid B Inhibits FLT4-induced Proliferation and Migration in Non-small Cell Lung Cancer.白头翁素 B 抑制非小细胞肺癌中 FLT4 诱导的增殖和迁移。
Anticancer Agents Med Chem. 2024;24(19):1419-1430. doi: 10.2174/0118715206313028240819103933.
4
Associations between Radiomics and Genomics in Non-Small Cell Lung Cancer Utilizing Computed Tomography and Next-Generation Sequencing: An Exploratory Study.利用计算机断层扫描和下一代测序技术研究非小细胞肺癌的放射组学与基因组学相关性：一项探索性研究。
Genes (Basel). 2024 Jun 18;15(6):803. doi: 10.3390/genes15060803.
本文引用的文献
1
Evolution of the Surgical Management of Lung Cancer Invading the Spine: A Single Center Experience.肺癌侵犯脊柱的外科治疗演变：单中心经验。
Curr Oncol. 2022 Apr 26;29(5):3061-3071. doi: 10.3390/curroncol29050248.
2
Fusions in Non-Small-Cell Lung Cancer: Evidence to Date.非小细胞肺癌中的融合基因：现有证据。
Curr Oncol. 2022 Jan 28;29(2):641-658. doi: 10.3390/curroncol29020057.
3
Contribution of the Idylla System to Improving the Therapeutic Care of Patients with NSCLC through Early Screening of Mutations.Idylla 系统通过早期筛查突变对改善 NSCLC 患者治疗护理的贡献。
Curr Oncol. 2021 Nov 3;28(6):4432-4445. doi: 10.3390/curroncol28060376.
4
Neoadjuvant Therapy in Lung Cancer: What Is Most Important: Objective Response Rate or Major Pathological Response?肺癌的新辅助治疗：什么最重要：客观缓解率还是主要病理缓解？
Curr Oncol. 2021 Oct 13;28(5):4129-4138. doi: 10.3390/curroncol28050350.
5
Feasibility of Stereotactic Body Radiation Therapy on Unresectable Stage III NSCLC with Peripheral Primary Tumor: A Prospective Study (GFPC 01-14).立体定向体部放射治疗对不可切除的周围型原发性Ⅲ期非小细胞肺癌的可行性：一项前瞻性研究（GFPC 01 - 14）
Curr Oncol. 2021 Sep 28;28(5):3804-3811. doi: 10.3390/curroncol28050324.
Zotero 插件